Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CS014 in Healthy Volunteers Following Single and Repeated Doses: A First-in-Human Study

The primary objective of this clinical trial is to evaluate the **safety** and **tolerability** of CS014 in healthy volunteers. This is the first administration of CS014 in humans, and understanding its safety profile is crucial for determining its potential therapeutic application in managing **cardiovascular disease**. The study will assess the levels of CS014 in the body and its effects following both single and repeated doses. This information is vital for establishing dosage guidelines and ensuring patient safety in future clinical applications.

The clinical trial involves participants diagnosed with **cardiovascular disease**. The study population includes both male and female subjects, with an age range spanning from adults to older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. Key inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and pharmacodynamics of CS014 in healthy volunteers. This is a Phase 1 trial, which is the first time CS014 is being administered to humans. The study employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The trial is set to commence on June 17, 2024, with an estimated completion date of April 15, 2025, indicating an overall duration of approximately 10 months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either a single or repeated dose of CS014 or a placebo. The sequence of study visits will include regular follow-up visits to monitor safety, collect blood samples for pharmacokinetic analysis, and assess any effects of the drug on the body. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather comprehensive data on the drug's effects.

The expected length of participant involvement will vary depending on the dosing regimen assigned, but it is anticipated to last several weeks to a few months. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is focused on **cardiovascular disease**, although the participants themselves are healthy volunteers, ensuring that the findings are applicable to the intended patient population in future studies.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is June 17, 2024, with an anticipated end date of April 15, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring biomarker levels or other relevant physiological responses. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but standard practices in Phase 1 trials often involve frequent monitoring and data collection at various timepoints throughout the study duration. The trial does not specify the use of particular tools or instruments for efficacy assessments. The focus remains on gathering preliminary data to inform subsequent phases of clinical research.